Roivant Sciences to Acquire Tectonic Therapeutic
Ticker: TECX · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1681087
| Field | Detail |
|---|---|
| Company | Tectonic Therapeutic, Inc. (TECX) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, gene-therapy, biotech
Related Tickers: ROIV
TL;DR
Roivant buying Tectonic! Gene therapy play.
AI Summary
Tectonic Therapeutic, Inc. announced on July 30, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Roivant Sciences Ltd. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition follows Tectonic's progress in developing its gene therapy platform.
Why It Matters
This acquisition by Roivant Sciences could accelerate the development and commercialization of Tectonic's gene therapy pipeline, potentially bringing new treatments to patients.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, which introduces uncertainty until completion.
Key Players & Entities
- Tectonic Therapeutic, Inc. (company) — Registrant
- Roivant Sciences Ltd. (company) — Acquiring entity
- July 30, 2024 (date) — Announcement date
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the primary business of Tectonic Therapeutic, Inc.?
Tectonic Therapeutic, Inc. is focused on developing a gene therapy platform.
Who is acquiring Tectonic Therapeutic, Inc.?
A subsidiary of Roivant Sciences Ltd. is acquiring Tectonic Therapeutic, Inc.
When is the acquisition expected to be completed?
The acquisition is expected to close in the fourth quarter of 2024.
What are the conditions for the acquisition to close?
The transaction is subject to customary closing conditions.
What was Tectonic Therapeutic's former company name?
Tectonic Therapeutic, Inc. was formerly known as AVROBIO, Inc. and AvroBio, Inc.
Filing Stats: 1,142 words · 5 min read · ~4 pages · Grade level 12.4 · Accepted 2024-07-30 16:15:13
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share TECX Nasdaq Global Market
Filing Documents
- d783068d8k.htm (8-K) — 32KB
- d783068dex991.htm (EX-99.1) — 17KB
- d783068dex992.htm (EX-99.2) — 55KB
- g783068ex99_2p10g1.jpg (GRAPHIC) — 250KB
- g783068ex99_2p11g1.jpg (GRAPHIC) — 309KB
- g783068ex99_2p12g1.jpg (GRAPHIC) — 381KB
- g783068ex99_2p13g1.jpg (GRAPHIC) — 296KB
- g783068ex99_2p14g1.jpg (GRAPHIC) — 269KB
- g783068ex99_2p15g1.jpg (GRAPHIC) — 344KB
- g783068ex99_2p16g1.jpg (GRAPHIC) — 364KB
- g783068ex99_2p17g1.jpg (GRAPHIC) — 233KB
- g783068ex99_2p18g1.jpg (GRAPHIC) — 307KB
- g783068ex99_2p19g1.jpg (GRAPHIC) — 485KB
- g783068ex99_2p1g1.jpg (GRAPHIC) — 306KB
- g783068ex99_2p20g1.jpg (GRAPHIC) — 263KB
- g783068ex99_2p21g1.jpg (GRAPHIC) — 357KB
- g783068ex99_2p22g1.jpg (GRAPHIC) — 460KB
- g783068ex99_2p23g1.jpg (GRAPHIC) — 254KB
- g783068ex99_2p24g1.jpg (GRAPHIC) — 326KB
- g783068ex99_2p25g1.jpg (GRAPHIC) — 213KB
- g783068ex99_2p26g1.jpg (GRAPHIC) — 323KB
- g783068ex99_2p27g1.jpg (GRAPHIC) — 291KB
- g783068ex99_2p28g1.jpg (GRAPHIC) — 231KB
- g783068ex99_2p29g1.jpg (GRAPHIC) — 349KB
- g783068ex99_2p2g1.jpg (GRAPHIC) — 662KB
- g783068ex99_2p30g1.jpg (GRAPHIC) — 337KB
- g783068ex99_2p31g1.jpg (GRAPHIC) — 276KB
- g783068ex99_2p32g1.jpg (GRAPHIC) — 308KB
- g783068ex99_2p33g1.jpg (GRAPHIC) — 309KB
- g783068ex99_2p34g1.jpg (GRAPHIC) — 427KB
- g783068ex99_2p35g1.jpg (GRAPHIC) — 258KB
- g783068ex99_2p36g1.jpg (GRAPHIC) — 273KB
- g783068ex99_2p37g1.jpg (GRAPHIC) — 268KB
- g783068ex99_2p38g1.jpg (GRAPHIC) — 172KB
- g783068ex99_2p39g1.jpg (GRAPHIC) — 306KB
- g783068ex99_2p3g1.jpg (GRAPHIC) — 167KB
- g783068ex99_2p40g1.jpg (GRAPHIC) — 334KB
- g783068ex99_2p41g1.jpg (GRAPHIC) — 230KB
- g783068ex99_2p42g1.jpg (GRAPHIC) — 264KB
- g783068ex99_2p43g1.jpg (GRAPHIC) — 256KB
- g783068ex99_2p44g1.jpg (GRAPHIC) — 250KB
- g783068ex99_2p45g1.jpg (GRAPHIC) — 299KB
- g783068ex99_2p46g1.jpg (GRAPHIC) — 184KB
- g783068ex99_2p47g1.jpg (GRAPHIC) — 283KB
- g783068ex99_2p48g1.jpg (GRAPHIC) — 232KB
- g783068ex99_2p49g1.jpg (GRAPHIC) — 403KB
- g783068ex99_2p4g1.jpg (GRAPHIC) — 598KB
- g783068ex99_2p50g1.jpg (GRAPHIC) — 298KB
- g783068ex99_2p51g1.jpg (GRAPHIC) — 246KB
- g783068ex99_2p52g1.jpg (GRAPHIC) — 203KB
- g783068ex99_2p53g1.jpg (GRAPHIC) — 200KB
- g783068ex99_2p54g1.jpg (GRAPHIC) — 324KB
- g783068ex99_2p55g1.jpg (GRAPHIC) — 318KB
- g783068ex99_2p56g1.jpg (GRAPHIC) — 216KB
- g783068ex99_2p5g1.jpg (GRAPHIC) — 388KB
- g783068ex99_2p6g1.jpg (GRAPHIC) — 317KB
- g783068ex99_2p7g1.jpg (GRAPHIC) — 355KB
- g783068ex99_2p8g1.jpg (GRAPHIC) — 329KB
- g783068ex99_2p9g1.jpg (GRAPHIC) — 266KB
- 0001193125-24-188881.txt ( ) — 23907KB
- tecx-20240730.xsd (EX-101.SCH) — 3KB
- tecx-20240730_lab.xml (EX-101.LAB) — 18KB
- tecx-20240730_pre.xml (EX-101.PRE) — 11KB
- d783068d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits Exhibit No. Description 99.1 Press release dated July 30, 2024. 99.2 Corporate Presentation dated July 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TECTONIC THERAPEUTIC, INC. Date: July 30, 2024 By: /s/ Daniel Lochner Daniel Lochner Chief Financial Officer